These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 27476777)

  • 1. Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases.
    Goodman AL; Osunkoya AO
    Hum Pathol; 2016 Nov; 57():160-164. PubMed ID: 27476777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.
    Ehsani L; Osunkoya AO
    Int J Clin Exp Pathol; 2014; 7(5):2544-50. PubMed ID: 24966967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
    Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
    Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive micropapillary urothelial carcinoma: a clinicopathologic study of 18 cases.
    Amin A; Epstein JI
    Hum Pathol; 2012 Dec; 43(12):2124-8. PubMed ID: 22939957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
    Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
    Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin expression in plasmacytoid, signet ring cell and micropapillary variants of urothelial carcinoma: comparison with usual-type high-grade urothelial carcinoma.
    Lim MG; Adsay NV; Grignon DJ; Osunkoya AO
    Mod Pathol; 2011 Feb; 24(2):241-7. PubMed ID: 20818341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive micropapillary carcinoma of urinary bladder: a clinicopathological study.
    Chatterjee D; Das A; Radotra BD
    Indian J Pathol Microbiol; 2015; 58(1):2-6. PubMed ID: 25673582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasive micropapillary urothelial carcinoma of the bladder.
    Lopez-Beltran A; Montironi R; Blanca A; Cheng L
    Hum Pathol; 2010 Aug; 41(8):1159-64. PubMed ID: 20381120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.
    Sasaki Y; Sasaki T; Kawai T; Morikawa T; Matsusaka K; Kunita A; Kume H; Aoki I; Homma Y; Fukayama M
    Int J Clin Exp Pathol; 2014; 7(2):699-708. PubMed ID: 24551292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma.
    Cox R; Epstein JI
    Am J Surg Pathol; 2011 Sep; 35(9):1337-42. PubMed ID: 21836490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stromal Lymphoid Response Status in Micropapillary Urothelial Carcinomas Diagnosed in Bladder Transurethral Resections and its Comparison with Conventional Urothelial Carcinomas.
    HacihasanoĞlu E; YÜcetaŞ U; OkÇu O; BehzatoĞlu K
    Turk Patoloji Derg; 2021; 37(1):26-31. PubMed ID: 32692402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
    Li J; Lu S; Lombardo K; Monahan R; Amin A
    Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical comparison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the urinary tract and typical invasive urothelial carcinoma with retraction artifact.
    Sangoi AR; Higgins JP; Rouse RV; Schneider AG; McKenney JK
    Mod Pathol; 2009 May; 22(5):660-7. PubMed ID: 19270645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
    Tsai YS; Tzai TS; Chow NH
    Urol Int; 2007; 79(3):210-6. PubMed ID: 17940352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications.
    Krüger S; Weitsch G; Büttner H; Matthiensen A; Böhmer T; Marquardt T; Sayk F; Feller AC; Böhle A
    Int J Cancer; 2002 Dec; 102(5):514-8. PubMed ID: 12432555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.